Idorsia Ltd (IDIA) - Net Assets

Latest as of September 2025: CHF-1.14 Billion CHF ≈ $-1.44 Billion USD

Based on the latest financial reports, Idorsia Ltd (IDIA) has net assets worth CHF-1.14 Billion CHF (≈ $-1.44 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF454.57 Million ≈ $574.70 Million USD) and total liabilities (CHF1.59 Billion ≈ $2.01 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Idorsia Ltd to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CHF-1.14 Billion
% of Total Assets	-249.85%
Annual Growth Rate	N/A
5-Year Change	-307.03%
10-Year Change	N/A
Growth Volatility	305.31

Idorsia Ltd - Net Assets Trend (2016–2024)

This chart illustrates how Idorsia Ltd's net assets have evolved over time, based on quarterly financial data. Also explore IDIA total asset value for the complete picture of this company's asset base.

Annual Net Assets for Idorsia Ltd (2016–2024)

The table below shows the annual net assets of Idorsia Ltd from 2016 to 2024. For live valuation and market cap data, see Idorsia Ltd market capitalisation.

Year	Net Assets	Change
2024-12-31	CHF-1.21 Billion ≈ $-1.53 Billion	-25.13%
2023-12-31	CHF-968.72 Million ≈ $-1.22 Billion	-46.56%
2022-12-31	CHF-660.96 Million ≈ $-835.63 Million	-734.29%
2021-12-31	CHF104.20 Million ≈ $131.74 Million	-82.20%
2020-12-31	CHF585.48 Million ≈ $740.21 Million	+256.25%
2019-12-31	CHF164.35 Million ≈ $207.78 Million	-75.01%
2018-12-31	CHF657.62 Million ≈ $831.42 Million	-11.07%
2017-12-31	CHF739.51 Million ≈ $934.94 Million	+45.58%
2016-12-31	CHF507.97 Million ≈ $642.21 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Idorsia Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 307163300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	CHF9.49 Million	%
Other Comprehensive Income	CHF2.86 Million	%
Other Components	CHF2.18 Billion	%
Total Equity	CHF-1.21 Billion	100.00%

Idorsia Ltd Competitors by Market Cap

The table below lists competitors of Idorsia Ltd ranked by their market capitalization.

Company	Market Cap
Shanghai Amarsoft Information & Technolgy Co Ltd SHE:300380	$759.47 Million
indie Semiconductor Inc NASDAQ:INDI	$759.79 Million
Suzhou Alton Electrical & Mechanical Industry Co. Ltd. SHE:301187	$759.90 Million
Sky Gold Limited NSE:SKYGOLD	$760.24 Million
Zehnder SW:ZEHN	$759.25 Million
Hefei Fengle Seed Co Ltd SHE:000713	$759.23 Million
EZTEC Empreendimentos e Participações S.A SA:EZTC3	$759.20 Million
Contec Medical Systems Co Ltd SHE:300869	$759.06 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Idorsia Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from -968,718,000 to -1,212,145,000, a change of -243,427,000.
Net loss of 263,757,000 reduced equity.
Share repurchases of 80,000 reduced equity.
Other comprehensive income decreased equity by 6,883,000.
Other factors increased equity by 27,293,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CHF-263.76 Million	-21.76%
Share Repurchases	CHF80.00K	-0.01%
Other Comprehensive Income	CHF-6.88 Million	-0.57%
Other Changes	CHF27.29 Million	+2.25%
Total Change	CHF-	%

Book Value vs Market Value Analysis

This analysis compares Idorsia Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	CHF4.24	CHF3.68	x
2017-12-31	CHF6.45	CHF3.68	x
2018-12-31	CHF5.26	CHF3.68	x
2019-12-31	CHF1.30	CHF3.68	x
2020-12-31	CHF4.10	CHF3.68	x
2021-12-31	CHF0.62	CHF3.68	x
2022-12-31	CHF-3.73	CHF3.68	x
2023-12-31	CHF-5.43	CHF3.68	x
2024-12-31	CHF-6.64	CHF3.68	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Idorsia Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.00%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -234.43%
• Asset Turnover: 0.22x
• Equity Multiplier: 0.00x
Recent ROE (0.00%) is above the historical average (-121.93%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2016	-65.42%	0.00%	0.00x	1.79x	CHF-386.37 Million
2017	-1.91%	-9.03%	0.12x	1.73x	CHF-88.81 Million
2018	-58.13%	-637.42%	0.04x	2.12x	CHF-452.86 Million
2019	-286.85%	-2076.70%	0.02x	5.82x	CHF-511.89 Million
2020	-76.03%	-620.31%	0.05x	2.45x	CHF-503.67 Million
2021	-608.99%	-1795.23%	0.02x	14.23x	CHF-645.02 Million
2022	0.00%	-852.60%	0.11x	0.00x	CHF-761.80 Million
2023	0.00%	-195.50%	0.30x	0.00x	CHF-201.05 Million
2024	0.00%	-234.43%	0.22x	0.00x	CHF-142.54 Million

Industry Comparison

This section compares Idorsia Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $290,510,224
Average return on equity (ROE) among peers: -38.98%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Idorsia Ltd (IDIA)	CHF-1.14 Billion	-65.42%	N/A	$759.27 Million
Addex Therapeutics Ltd (ADXN)	$33.84 Million	-92.04%	0.29x	$7.10 Million
BB Biotech AG (BION)	$1.91 Billion	10.59%	0.00x	$2.25 Billion
Basilea Pharmaceutica AG (BSLN)	$125.38 Million	-47.04%	0.20x	$699.48 Million
Evolva Holding SA (EVE)	$21.86 Million	-39.62%	1.03x	$7.08 Million
Molecular Partners AG (MOLN)	$135.79 Million	-13.71%	0.36x	$145.86 Million
Newron Pharmaceuticals SpA (NWRN)	$29.28 Million	-80.19%	0.42x	$360.88 Million
Relief Therapeutics Holding AG (RLF)	$14.30 Million	-52.18%	0.39x	$36.33 Million
Santhera Pharmaceuticals Holding AG (SANN)	$104.47 Million	-42.74%	0.08x	$244.59 Million
Xlife Sciences AG (XLS)	$235.23 Million	6.08%	1.08x	$122.27 Million

About Idorsia Ltd

SW:IDIA Switzerland Biotechnology

Market Cap

$1.14 Billion

CHF905.23 Million CHF

Market Cap Rank

#10420 Global

#126 in Switzerland

Share Price

CHF3.68

Change (1 day)

+1.60%

52-Week Range

CHF1.28 - CHF4.70

All Time High

CHF33.62